A new tool that uses machine learning for drug discovery predicts how molecules will influence gene expression.
Researchers discover a protein that connects GLP-1 drugs to long-term, broad genomic responses that can promote pancreatic ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, ...
Haploinsufficiency occurs when one wild-type and one pathogenic allele fail to produce enough protein for healthy function, leading to disease. With over 300 known haploinsufficiency disorders, these ...
Sizeable differences in gene expression means and ratios—based solely upon where genes are located on a plasmid (gene syntax)—have been discovered by researchers at Dartmouth College. This new ...
PerturbAI has emerged from stealth mode with the release of the world’s largest in vivo CRISPR atlas as described in a preprint on Biorxiv. The study profiled over 7.7 million cells from the brains of ...
Palisade Bio Inc. (NASDAQ:PALI) is one of the best growth stocks to buy right now. On February 23, Palisade Bio presented translational data from its Phase 1b study of PALI-2108. The findings ...
Akamis Bio, a clinical-stage oncology company, has raised $60 million in Series A funding that will drive continued development of NG-350A, a new gene therapy based on its proprietary tumor-specific ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results